Venture Capital

Tranquis Therapeutics Launches With $30M Series A Funding To Advance Novel Immuno-neurology Approach To Treating Neurodegenerative And Aging-related Diseases

by vcaonline.com posted 2months ago 228 views

Tranquis Therapeutics Launches with $30 Million Series A Funding to Advance Novel Immuno-Neurology Approach to Treating Neurodegenerative and Aging-related Diseases

- Platform based on groundbreaking research from the laboratory of Professor Edgar Engleman, MD, at Stanford University indicating that myeloid immune cell dysfunction underlies a variety of nervous system disorders -

- Initial development focused in orphan diseases such as Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, with planned expansion into more prevalent diseases such as Parkinson’s and Alzheimer’s -

SAN MATEO, Calif., July 9, 2020-- Tranquis Therapeutics, a private immuno-neurology company, launched today with $30 million in Series A funding committed to ...

In this article